# An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

> **NCT02890992** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 42 (actual)

## Conditions studied

- Hypercholesterolaemia

## Interventions

- **DRUG:** alirocumab SAR236553 (REGN727)
- **DRUG:** statins
- **DRUG:** ezetimibe
- **DRUG:** cholestyramine
- **DRUG:** fenofibrate
- **DRUG:** omega-3 fatty acids
- **DRUG:** nicotinic acid

## Key facts

- **NCT ID:** NCT02890992
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-15
- **Primary completion:** 2018-09-13
- **Final completion:** 2019-02-22
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02890992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02890992, "An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02890992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*